Physician profile
Daniel Parrinello
NPI 1609453554
$495.48
in general payments reported to CMS, 2019-2025
16 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $94.10 · 2023: $98.19 · 2024: $35.08 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $141.17 | 2025 | Accolade Sr |
| Ucb, INC. | $61.25 | 2023-2025 | Briviact, Fintepla |
| Teva Pharmaceuticals USA, INC. | $34.72 | 2022-2025 | Austedo Xr |
| Sk Life Science, INC. | $31.96 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $29.08 | 2022 | |
| Genentech USA, INC. | $28.00 | 2025 | Ocrevus Zunovo |
| Biogen, INC. | $23.61 | 2025 | Vumerity |
| Alnylam Pharmaceuticals INC. | $18.92 | 2023 | Onpattro |
| Jazz Pharmaceuticals INC. | $18.68 | 2023 | Epidiolex |
| Biohaven Pharmaceutical Holding Company LTD. | $17.19 | 2022 | |
| Argenx US, INC. | $16.61 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.19 | 2024 | Ultomiris |
| Emd Serono, INC. | $15.71 | 2025 | |
| Amneal Pharmaceuticals LLC | $14.60 | 2022 | |
| Acadia Pharmaceuticals INC | $14.04 | 2025 | Nuplazid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.75 | 2025 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Parrinello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.